Baird analyst Michael Ha lowered the firm’s price target on Elevance Health (ELV) to $297 from $492 and keeps a Neutral rating on the shares as part of an update on the managed care and healthcare facilities group. The firm is increasingly cautious on Medicaid and the healthcare exchange.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Elevance Health’s (ELV) Earnings Blunder Entices Bullish Stock Option Traders
- Insiders Are Betting Big on These 2 Stocks – Should You Follow Their Lead?
- Elevance Health price target lowered to $327 from $358 at Barclays
- Target downgraded, Dollar Tree upgraded: Wall Street’s top analyst calls
- Argus downgrades Elevance Health to Hold on ongoing profit pressures